191 related articles for article (PubMed ID: 10992445)
21. Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.
Rousselle JC; Callister SM; Schell RF; Lovrich SD; Jobe DA; Marks JA; Wieneke CA
J Infect Dis; 1998 Sep; 178(3):733-41. PubMed ID: 9728542
[TBL] [Abstract][Full Text] [Related]
22. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
23. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B.
Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA
J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061
[TBL] [Abstract][Full Text] [Related]
24. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.
Probert WS; LeFebvre RB
Infect Immun; 1994 May; 62(5):1920-6. PubMed ID: 8168958
[TBL] [Abstract][Full Text] [Related]
25. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
26. DbpA, but not OspA, is expressed by Borrelia burgdorferi during spirochetemia and is a target for protective antibodies.
Cassatt DR; Patel NK; Ulbrandt ND; Hanson MS
Infect Immun; 1998 Nov; 66(11):5379-87. PubMed ID: 9784547
[TBL] [Abstract][Full Text] [Related]
27. Specific immune response to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies.
Ikushima M; Matsui K; Yamada F; Kawahashi S; Nishikawa SK
FEMS Immunol Med Microbiol; 2000 Sep; 29(1):15-21. PubMed ID: 10967255
[TBL] [Abstract][Full Text] [Related]
28. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
[TBL] [Abstract][Full Text] [Related]
29. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
30. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
[TBL] [Abstract][Full Text] [Related]
31. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
32. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
[TBL] [Abstract][Full Text] [Related]
33. Long-term protection of mice from Lyme disease by vaccination with OspA.
Fikrig E; Barthold SW; Kantor FS; Flavell RA
Infect Immun; 1992 Mar; 60(3):773-7. PubMed ID: 1541551
[TBL] [Abstract][Full Text] [Related]
34. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.
Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM
Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698
[TBL] [Abstract][Full Text] [Related]
35. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.
Willett TA; Meyer AL; Brown EL; Huber BT
Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1303-8. PubMed ID: 14742868
[TBL] [Abstract][Full Text] [Related]
36. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
Luke CJ; Huebner RC; Kasmiersky V; Barbour AG
Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies with in vitro borreliacidal activities define the outer surface proteins A and B of Borrelia burgdorferi.
Moskophidis M; Luther B
Zentralbl Bakteriol; 1993 Jun; 279(2):201-13. PubMed ID: 8219491
[TBL] [Abstract][Full Text] [Related]
38. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
[TBL] [Abstract][Full Text] [Related]
39. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
Lovrich SD; Jobe DA; Schell RF; Callister SM
Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
[TBL] [Abstract][Full Text] [Related]
40. Borrelia burgdorferi-pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes.
Mbow ML; Zeidner N; Panella N; Titus RG; Piesman J
Infect Immun; 1997 Aug; 65(8):3386-90. PubMed ID: 9234802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
